Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 18/20 | 0.60 |
| ▸ | EGFR | P00533 | 15/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262436 | 0.89 | ERBB2 (0.61) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL1093852 | 0.85 | EGFR (0.63) | ERBB2EGFRAURKA | |
| SCHEMBL35210264 | 0.81 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL19089286 | 0.81 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL30213694 | 0.81 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL23859935 | 0.80 | ERBB2 (0.57) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL2989878 | 0.80 | ERBB2 (0.73) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL1097212 | 0.79 | EGFR (0.68) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL27751267 | 0.79 | ERBB2 (0.58) | ERBB2EGFRERBB3ERBB4AURKA | |
| SCHEMBL4864889 | 0.79 | ERBB2 (0.67) | ERBB2EGFRERBB3ERBB4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | ERBB2 124/4885EGFR 1201/4885ERBB3 348/4885 |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | ERBB2 124/4885EGFR 1201/4885ERBB3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.